Home > Journals > Italian Journal of Dermatology and Venereology > Past Issues > Giornale Italiano di Dermatologia e Venereologia 2019 August;154(4) > Giornale Italiano di Dermatologia e Venereologia 2019 August;154(4):418-24

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

REVIEW   

Giornale Italiano di Dermatologia e Venereologia 2019 August;154(4):418-24

DOI: 10.23736/S0392-0488.18.06202-8

Copyright © 2018 EDIZIONI MINERVA MEDICA

language: English

Psoriasis and the TNF/IL23/IL17 axis

Kazuhisa FURUE 1, Takamichi ITO 1, Gaku TSUJI 1, Takafumi KADONO 2, Masutaka FURUE 1

1 Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; 2 Department of Dermatology, St. Marianna University School of Medicine, Kawasaki, Japan



The excellent response of psoriasis to anti-TNF-α(TNF)/IL23/IL17A biologics implies a crucial role for the TNF/IL23/IL17 axis in developing psoriasis. In addition to the TNF/IL23/IL17 axis provided by immune cells, current evidence points to an important contribution of TNF, IL23 and IL17C produced from non-hematopoietic keratinocytes. Therefore, crosstalk between immune cells and keratinocytes forms a multilayered feed-forward loop to accelerate the TNF/IL23/IL17A axis. Many biologics have already been licensed or are under clinical trials. Given that the IL-17 signature is more upregulated in the skin than in synovium in psoriatic arthritis, anti-IL-23/IL-17 agents seem to be superior to anti-TNF-α remedies in the treatment of skin lesions. In this review, we summarize recent topics in psoriasis and the TNF/IL23/IL17 axis.


KEY WORDS: Psoriasis; Tumor necrosis factor-alpha; Interleukin-23; Interleukin-17

top of page